Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Amerikaanse aandelen « Terug naar discussie overzicht

Phunware Inc.

19.112 Posts, Pagina: « 1 2 3 4 5 6 ... 881 882 883 884 885 886 887 888 889 890 891 ... 952 953 954 955 956 » | Laatste

Omlaag ↓

Jager63 21 november 2022 16:50

ir.stockpr.com/lmfunding/news/detail/86

LMfunding

The Pigeonman 21 november 2022 20:24

quote:
Hansvdz schreef op 21 november 2022 16:01:
[...]

En maar weer bijgekocht.

Groot gelijk! :-)

Jager63 22 november 2022 05:48

Goeiemorgen

Jager63 22 november 2022 05:49

u13354397.ct.sendgrid.net/ls/click?up...

VIRGIN GALACTIC

The Pigeonman 22 november 2022 06:46

quote:
Jager63 schreef op 22 november 2022 05:48:
Goeiemorgen

Morge Jan, vandaag een dagje vrij.

Jager63 22 november 2022 08:32

www.bing.com/ck/a?!&&p=0e580e...

PHUNWARE

Jager63 22 november 2022 10:36

PHUNWARE min 22% in 5 dagen!

Waar blijven de (terug) kopers?

Jager63 22 november 2022 10:38

Tot nu toe in 1 jaar min 67%!!

Tijd voor herstel zou je zeggen.

Jager63 22 november 2022 12:05

www.msn.com/nl-nl/geldzaken/nieuws/to...

Gaat nog lang duren!

Jager63 22 november 2022 12:12

www.bing.com/ck/a?!&&p=37f641...

Dit is ook geen succes geworden!

Jager63 22 november 2022 12:15

www.iexprofs.nl/Column/761662/Must-re...

Het is niet anders.

Jager63 22 november 2022 12:31

1 BITCOIN:

15.322,83 Euro
Laatst bijgewerkt · 22 november om 11:17 UTC

Dit is ook een gekkenhuis!

Jager63 22 november 2022 12:35

www.msn.com/nl-nl/geldzaken/nieuws/cr...

BITCOIN

Jager63 22 november 2022 15:51

Morgen maar eens naar de oogarts, want geloof mijn ogen niet meer.

Hansvdz 22 november 2022 16:21

quote:
Jager63 schreef op 22 november 2022 15:51:
Morgen maar eens naar de oogarts, want geloof mijn ogen niet meer.

Haha. Ja geduld hebben is niet voor iedereen weggelegd. Toch heb ik dat.

Jager63 22 november 2022 16:22

irreach.com/lt.php?c=75840&m=8110...

APPLIED UV

Jager63 22 november 2022 16:27

quote:
Hansvdz schreef op 22 november 2022 16:21:
[...]

Haha. Ja geduld hebben is niet voor iedereen weggelegd. Toch heb ik dat.

Klopt, dat heb ik niet en daarom wilde ik begin dit jaar helemaal cash gaan.

Maar daghandel vind ik geweldig.

Dus tegen beter weten in steeds te duur gekocht, en dan blijf je zitten met de troep.

Jager63 23 november 2022 05:49

Goeiemorgen

Jager63 23 november 2022 07:25

PHARMING GROUP

Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kd inhibitor under investigation for APDS, a rare primary immunodeficiency
Leiden, The Netherlands, November 23, 2022
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that new clinical data for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, an investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be presented by V. Koneti Rao, MD, FRCPA, staff physician in the Primary Immune Deficiency Clinic at the National Institute of Health in Bethesda, Maryland, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, in New Orleans, Louisiana taking place from Saturday, December 10 through Tuesday, December 13, 2022.

Information regarding Pharming's data presentation can be found below, and on the ASH conference website: www.hematology.org/meetings/annual-me...

Presentation title: Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kd Inhibitor Leniolisib for Patients with Activated PI3Kd Delta Syndrome (APDS) through December 2021

Presentation type: oral

Session name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans

Abstract number: 608

Session date and time: Monday, December 12, 2022 from 10:30AM – 12:30PM CST

Presentation date and time: Monday, December 12, 2022 at 10:45AM CST

Location: Room: Ernest N. Morial Convention Center, 278-282

About Activated Phosphoinositide 3-Kinase d Syndrome (APDS)
APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3Kd (phosphoinositide 3-kinase delta) pathway.1,2 Balanced signaling in the PI3Kd pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.1,3 APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.

About Leniolisib
Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3Kd is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3). Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Unlike PI3Ka and PI3Kß, which are ubiquitously expressed, PI3K? and PI3K? are expressed primarily in cells of hematopoietic origin. The central role of PI3K? in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3K? is a valid and potentially effective therapeutic target for immune diseases such as APDS. To date, leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com

Forward-Looking Statements
This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:
Pharming Group, Leiden, The Netherlands
Heather Robertson, Investor Relations & Corporate Communications Manager
Tel: +31 71 524 7400
E-Mail: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell / Alex Shaw / Amy Byrne
Tel: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
Tel: +31 6 53 81 64 27
E-Mail: pharming@lifespring.nl

US PR:
Ethan Metelenis
Tel: +1 (917) 882 9038
E-Mail: Ethan.Metelenis@precisionvh.com

EU PR:
Dan Caley
Tel: +44 (0) 787 546 8942
E-Mail: Dan.caley@aprilsix.com

Jager63 23 november 2022 07:54

www.wsj.com/articles/nasdaq-freezes-c...

ADDENTAX (heeft me ook flink geld gekost).

Nu maar wachten op een spike, evenals bij PHUNWARE.

19.112 Posts, Pagina: « 1 2 3 4 5 6 ... 881 882 883 884 885 886 887 888 889 890 891 ... 952 953 954 955 956 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	891,10	+3,66	+0,41%	15:31
AMX	928,07	+4,47	+0,48%	15:30
ASCX	1.170,96	-2,17	-0,18%	15:16
BEL 20	3.931,13	+17,76	+0,45%	15:31
Germany40^	18.137,70	+136,10	+0,76%	15:30
US30^	38.831,96	+140,13	+0,36%	15:25
US500^	5.149,39	+21,86	+0,43%	15:31
Nasd100^	17.947,32	+53,36	+0,30%	15:31
Japan225^	38.648,58	+322,53	+0,84%	13:51
WTI	78,50	+0,39	+0,50%	15:30
Brent	83,28	+0,43	+0,52%	15:30
EUR/USD	1,0783	+0,0019	+0,18%	15:31
BTC/USD	63.593,07	+1.005,00	+1,61%	15:31
Gold spot	2.324,11	+22,36	+0,97%	15:31